Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors
Status:
Terminated
Trial end date:
2019-10-15
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess the safety and tolerability of multiple doses of a
human monoclonal antibody (BAY1093884) given under the skin in subjects with hemophilia A or
B. This antibody was intended to protect from bleeds by inhibiting a substance (Tissue Factor
Pathway Inhibitor, TFPI) that reduces the ability of the body to form blood clots.
Phase:
Phase 2
Details
Lead Sponsor:
Bayer
Treatments:
Factor VIII Immunoglobulin G Immunoglobulins Lipoprotein-associated coagulation inhibitor